Agilon Health, Inc. has announced robust second-quarter 2026 financial outcomes, exceeding its own projections for both medical margin and adjusted EBITDA. The company recorded revenue of approximately $1.49 billion, marking a 7% increase from the second quarter of 2025. This growth was primarily fueled by enhanced benchmark rates and a rise in risk adjustment revenue. Adjusted EBITDA reached $70 million, significantly outperforming the mid-point of management's initial guidance by roughly $50 million, attributed to favorable medical expense developments and revised risk scores. The medical margin saw a substantial improvement, climbing to $197 million from a negative $53 million in the corresponding period of 2025, reflecting improved operational efficiency and a $22 million favorable impact from prior year developments. Based on these strong results, the company has revised its full-year 2026 revenue guidance upwards to a range of $5.78 billion to $5.86 billion, and its adjusted EBITDA guidance to $75 million to $95 million, a substantial increase from the previous $10 million to $40 million range. The medical margin guidance for the full year has also been adjusted to between $465 million and $505 million, anticipating increased risk adjustment revenue and lower projected cost trends.
Despite the strong financial performance, the company reported a decrease in membership for both Medicare Advantage and ACO REACH programs. Medicare Advantage membership stood at 437,000 at the end of the quarter, a 12% reduction compared to the previous year, a result of a deliberate strategy focusing on profitable contracts. Similarly, ACO REACH membership saw a slight decrease of 3% to 112,000 beneficiaries. The second quarter's ACO REACH EBITDA contribution was $7 million, aligning with internal expectations, and the full-year guidance for ACO REACH EBITDA remains unchanged at $25 million to $30 million. Cash and marketable securities totaled $257 million as of June 30, 2026, complemented by $83 million in off-balance sheet cash held by ACO entities, with a year-end cash projection of at least $125 million. New CEO Tim O'Rourke, who joined in May, emphasized the company's commitment to strengthening physician partnerships, standardizing best practices, and leveraging AI to enhance patient care and operational workflows, noting that AI acts as a "force multiplier for primary care." He also highlighted the success of clinical pathways, such as the heart failure program, which has drastically reduced inpatient first diagnosis rates, showcasing the effectiveness of early identification and intervention.
Agilon Health is actively evolving its strategic approach to healthcare delivery, underscoring the critical role of strong physician relationships, advanced data analytics, and technological innovation. The organization believes its unique model, which empowers primary care physicians with enhanced financial and technological support, is central to the future of value-based care. By integrating solutions directly into daily workflows, Agilon and its partners are better positioned to improve patient outcomes and manage healthcare costs more effectively. The company's ongoing efforts to refine clinical pathways for chronic conditions like heart failure, COPD, and dementia, along with the strategic deployment of AI tools, demonstrate a forward-looking commitment to transforming healthcare. This holistic approach, combining sophisticated technology with local clinical expertise, is designed to reduce variability in care, facilitate earlier interventions, and ultimately lead to a more efficient and patient-centered healthcare system.
